A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents

Cornea

Volumn 25, Issue 5, 2006, Pages 597-602

  Vasseneix, Caroline ^a   Gargala, Gilles ^a,b   François, Arnaud ^a   Hellot, Marie France ^a   Duclos, Célia ^a   Muraine, Marc ^a   Benichou, Jacques ^a   Ballet, Jean Jacques ^b   Brasseur, Gérard ^a   Favennec, Loïc ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

^b CHU Clemenceau   (France)

Author keywords

Acanthamoeba polyphaga; Hexamidine diisethionate; Miltefosine; Polyhexamethylene biguanide; Rat keratitis model

Indexed keywords

BETAMETHASONE; HEXAMIDINE ISETIONATE; MILTEFOSINE; POLY(HEXAMETHYLENEBIGUANIDE); ANTIPROTOZOAL AGENT; BENZAMIDINE DERIVATIVE; BIGUANIDE DERIVATIVE; DRUG DERIVATIVE; GLUCOCORTICOID; HEXAMIDINE; PHOSPHORYLCHOLINE;

ACANTHAMOEBA; ACANTHAMOEBA KERATITIS; ACANTHAMOEBA POLYPHAGA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG POTENTIATION; HISTOPATHOLOGY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TROPHOZOITE; ANIMAL; CHRONIC DISEASE; CORNEA STROMA; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; GERMFREE ANIMAL; ISOLATION AND PURIFICATION; METHODOLOGY; PARASITOLOGY; PATHOLOGY; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION;

ACANTHAMOEBA; ACANTHAMOEBA KERATITIS; ADMINISTRATION, TOPICAL; ANIMALS; ANTIPROTOZOAL AGENTS; BENZAMIDINES; BETAMETHASONE; BIGUANIDES; CHRONIC DISEASE; CORNEAL STROMA; DISEASE MODELS, ANIMAL; DRUG EVALUATION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; MALE; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; RATS; RATS, SPRAGUE-DAWLEY; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 33746763085     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000214213.37447.11     Document Type: Article

References (43)

1. Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol.2004;34:1001- 1027.
2. Duguid IG, Dart JK, Morlet N, et al. Outcome of Acanthamoeba keratitis treated with polyhexamethylene biguanide and propamidine. Ophthalmology. 1997;104:1587-1592.
3. Claerhout I, Goegebuer A, Van Den Broecke C, et al. Delay in diagnosis and outcome of Acanthamoeba keratitis. Graefes Arch Clin Exp Ophthalmol. 2004;242:648-653.
4. Yang Z, Cao Z, Panjwani N. Pathogenesis of Acanthamoeba keratitis: carbohydrate-mediated host-parasite interactions. Infect Immun. 1997;65:439-445.
5. Niederkorn JY, Alizadeh H, Leher H, et al. The pathogenesis of Acanthamoeba keratitis. Microbes Infect. 1999;1:437-443.
6. Elder MJ, Kilvington S, Dart JKG. A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba Keratitis. Invest Ophthalmol Vis Sci. 1994;35:1059-1064.
7. Tseng SH, Lin SC, Chen FK. Is polyhexamethylene biguanide alone effective for Acanthamoeba keratitis? Cornea. 1998;17:345-347.
8. Khan NA. Pathogenesis of Acanthamoeba infections. Microb Pathog. 2003;34:277-285.
9. Badenoch PR, Johnson AM, Christy PE, et al. Pathogenicity of Acanthamoeba and a Corynebacterium in the rat cornea. Arch Ophthalmol. 1990;108:107-112.
10. Côté MA, Irvine JA, Rao NA, et al. Evaluation of the rabbit as a model of Acanthamoeba keratitis. Rev Infect Dis. 1991;13:443-444.
11. John T, Lin J, Sahm D, et al. Effects of corticosteroids in experimental Acanthamoeba keratitis. Rev Infect Dis. 1991;13:440-442.
12. Paniagua-Crespo E, Tsouria-Belaid A, Bello C, et al. Kératite amibienne à Acanthamoeba sp. L'infection par HSV1 aurait-elle un rôle? J Fr Ophtalmol. 1991;14:25-31.
13. He Y, McCulley JP, Alizadeh H, et al. A pig model of Acanthamoeba keratitis: transmission via contaminated contact lenses. Invest Ophthalmol Vis Sci. 1992;33:126-133.
14. Van Klink F, Alizadeh H, He Y, et al. The role of contact lenses, trauma, and langerhans cells in a chinese hamster model of Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1993;34:1937-1944.
15. McClellan K, Howard K, Niederkorn JY, et al. Effect of steroids on Acanthamoeba cysts and trophozoites. Invest Ophthalmol Vis Sci. 2001;42:2885-2893.
16. Schuster FL. Cultivation of pathogenic and opportunistic free-living amebas. Clin Microbiol Rev. 2002;15:342-354.
17. Grossniklaus HE, Waring GO, Akor C, et al. Evaluation of hematoxylin and eosin and special strains for the detection of acanthameoba keratitis in penetrating keratoplasty. Am J Ophthalmol. 2003;136:520-526.
18. Alizadeh H, Silvany RE, Meyer DR, et al. In vitro amoebicidal activity of propamidine isethionate against Acanthamoeba species and toxicity to corneal tissues. Cornea. 1997;16:94-100.
19. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983;11:427-433.
20. Larkin DFP, Kilvington S, Dart JKG. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology. 1992;99:185-191.
21. Hughes R, Heaselgrave W, Kilvington S. Acanthamoeba polyphaga strain age and method of cyst production influence the observed efficacy of therapeutic agents and contact lens disinfectants. Antimicrob Agents Chemother. 2003;47:3080-3084.
22. Perez-Santonja JJ, Kilvington S, Hughes R, et al. Persistently culture positive Acanthamoeba keratitis. Ophthalmology. 2003;110:1593-1600.
23. Brasseur G, Favennec L, Perrine D, et al. Successful treatment of Acanthamoeba keratitis by hexamidine. Cornea. 1994;13:459-462.
24. Panda A, Das GK, Biswas NR, et al. Therapy of Acanthamoeba keratitis - an experimental study. Indian J Physiol Pharmacol. 2000;44:363-367.
25. Larkin DFP, Easty DL. Experimental Acanthamoeba keratitis: I. Preliminary findings. Br J Ophthalmol. 1990;74:551-555.
26. Mathers W, Stevens G, Rodriguez M, et al. Immunopathology and electron microscopy of Acanthamoeba keratitis. Am J Ophthalmol. 1987;103:626-635.
27. Lindquist TD. Treatment of Acanthamoeba keratitis. Cornea. 1998;17:11-16.
28. Niederkorn JY, Ubelaker JE, McCulley JP, et al. Susceptibility of corneas from various animal species to in vitro binding and invasion by Acanthamoeba castellanii. Invest Ophthalmol Vis Sci. 1992;33:104-112.
29. Alizadeh H, He YG, McCulley JP, et al. Successful immunization against Acanthamoeba keratitis in a pig model. Cornea. 1995;14:180-186.
30. Leher H, Kinoshita K, Alizadeh H, et al. Impact of oral immunization with Acanthamoeba antigens on parasite adhesion and corneal infection. Invest Ophthalmol Vis Sci. 1998;39:2337-2343.
31. Leher H, Zaragoza F, Taherzadeh S, et al. Monoclonal IgA antibodies protect against Acanthamoeba keratitis. Exp Eye Res. 1999;69:75-84.
32. Hurt M, Apte S, Leher H, et al. Exacerbation of Acanthamoeba keratitis in animals treated with anti-macrophage inflammatory protein 2 or antineutrophil antibodies. Infect Immun. 2001;69:2988-2995.
33. Niederkorn JY. The role of the innate and adaptive immune responses in Acanthamoeba keratitis. Arch Immunol Therap Exp. 2002;50:53-59.
34. Ruddell TJ, Easty DL. Drug therapy in a murine model of Acanthamoeba keratitis. Eye. 1995;9:142-144.
35. Schaumberg DA, Snow KK, Dana MR. The epidemic of Acanthamoeba keratitis. Where do we stand? Cornea. 1998;17:3-10.
36. Cardine S, Bourcier T, Chaumeil C, et al. Prise en charge clinique et pronostic des kératites amibiennes. J Fr Ophtalmol. 2002;25:1007-1013.
37. Walochnik J, Duchêne M, Seifert K, et al. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother. 2002;46:695-701.
38. Kumar R, Lloyd D. Recent advances in the treatment of Acanthamoeba keratitis. Clin Infect Dis. 2002;35:434-441.
39. Lin CP, Boehnke M. Effect of fortified antibiotic solutions on corneal epithelial wound healing. Cornea. 2000;19:204-206.
40. Perrine D, Barbier D, Chenu JP, et al. Proposition de protocole simple pour l'évaluation de l'activité de collyres sur les amibes du genre Acanthamoeba. Bull Soc Fr Parasitol. 1990;8:189-192.
41. Perrine D, Chenu JP, Georges P, et al. Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. Antimicrob Agents Chemother. 1995;39:339-342.
42. Kilvington S, Hughes R, Byas J, et al. Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba isolates. Antimicrob Agents Chemother. 2002;46:2007-2009.
43. Wysenbeek YS, Blank-Porat D, Harizman N, et al. The reculture technique. Individualizing the treatment of Acanthamoeba keratitis. Cornea. 2000;19:464-467.